[1]
|
Storm, D.R., Rosenthal, K.S. and Swanson, P.E. (1977) Polymyxin and Related Peptide Antibiotics. Annual Review of Biochemistry, 46, 723-763.
https://doi.org/10.1146/annurev.bi.46.070177.003451
|
[2]
|
Nakajima, S. (1965) Clinical Use of Colimycin Fotic Solution. Jibiinkoka Otolaryngology, 37, 693.
|
[3]
|
Ohzawa, R. (1965) The Use of Colimycin Eardrops. Jibiinkoka Otolaryngology, 37, 585.
|
[4]
|
Falagas, M.E., Kasiakou, S.K. and Saravolatz, L.D. (2005) Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. Clinical Infectious Diseases, 40, 1333-1341.
https://doi.org/10.1086/429323
|
[5]
|
Cai, Y., Chai, D., Wang, R., Liang, B. and Bai, N. (2012) Colistin Resistance of Acinetobacter baumannii: Clinical Reports, Mechanisms and Antimicrobial Strategies. Journal of Antimicrobial Chemotherapy, 67, 1607-1615.
https://doi.org/10.1093/jac/dks084
|
[6]
|
Jeannot, K., Bolard, A. and Plésiat, P. (2017) Resistance to Polymyxins in Gram-Negative Organisms. International Journal of Antimicrobial Agents, 49, 526-535. https://doi.org/10.1016/j.ijantimicag.2016.11.029
|
[7]
|
Al-Tawfiq, J.A., Laxminarayan, R. and Mendelson, M. (2017) How Should We Respond to the Emergence of Plasmid-Mediated Colistin Resistance in Humans and Animals? International Journal of Infectious Diseases, 54, 77-84.
|
[8]
|
Li, J., Nation, R.L., Turnidge, J.D., et al. (2006) Colistin: The Re-Emerging Antibiotic for Multidrug Resistant Gram-Negative Bacterial Infection. Lancet, 9, 589-601.
|
[9]
|
Karvanen, M. (2013) Optimization of Colistin Dosage in the Treatment of Multiresistant Gram-Negative Infections (Dissertation). Uppsala Universiteit, Uppsala.
|
[10]
|
Leangapichart, T., Gautret, P., Brouqui, P., Mimish, Z., Raoult, D. and Rolain, J.-M. (2016) Acquisition of mcr-1 Plasmid-Mediated Colistin Resistance in Escherichia coli and Klebsiella pneumoniae during Hajj 2013 and 2014. Antimicrobial Agents and Chemotherapy, 60, 6998-6999. https://doi.org/10.1128/AAC.01486-16
|
[11]
|
Cara, A.K.S., Zaidi, S.T.R. and Suleman, F. (2018) Cost-Effectiveness Analysis of Low versus High Dose Colistin in the Treatment of Multi-Drug Resistant Pneumonia in Saudi Arabia. International Journal of Clinical Pharmacy, 40, 1051-1058.
https://doi.org/10.1007/s11096-018-0713-x
|
[12]
|
Rana, M.A., Rahman, B.A., Mady, A.F., Odat, M.A., AlHarthy, A., Ramadan Oel, S., Mumtaz, S.A. and Omrani, A.S. (2014) Intra-Pleural Colistin Methanesulfonate Therapy for Pleural Infection Caused by Carbapenem-Resistant Acinetobacter Baumannii: A Successful Case Report. Infectious Disease Reports, 6, 5413.
https://doi.org/10.4081/idr.2014.5413
|
[13]
|
Bukhary, Z., Mahmood, W., Al-Khani, A. and Al-Abdely, H.M. (2005) Treatment of Nosocomial Meningitis Due to a Multidrug Resistant Acinetobacter baumannii with Intraventricular Colistin. Saudi Medical Journal, 26, 656-658.
|
[14]
|
Al Shirawi, N., Memish, Z.A., Cherfan, A. and Al Shimemeri, A. (2006) Post-Neurosurgical Meningitis Due to Multidrug-Resistant Acinetobacter baumanii Treated with Intrathecal Colistin: Case Report and Review of the Literature. Journal of Chemotherapy, 18, 554-558. https://doi.org/10.1179/joc.2006.18.5.554
|
[15]
|
Rico Caballero, V., Almarzoky Abuhussain, S., Kuti, J.L. and Nicolau, D.P. (2018) Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 62, pii: e02384-17. https://doi.org/10.1128/AAC.02384-17
|
[16]
|
Garbati, M.A., Abdulhak, A.B., Baba, K. and Sakkijha, H. (2013) Infection Due to Colistin-Resistant Enterobacteriaceae in Critically Ill Patients. Journal of Infection in Developing Countries, 7, 713-719. https://doi.org/10.3855/jidc.2851
|
[17]
|
Baadani, A.M., Thawadi, S.I., El-Khizzi, N.A. and Omrani, A.S. (2013) Prevalence of Colistin and Tigecycline Resistance in Acinetobacter baumannii Clinical Isolates from 2 Hospitals in Riyadh Region over a 2-Year Period. Saudi Medical Journal, 34, 248-253.
|
[18]
|
Uz Zaman, T., Albladi, M., Siddique, M.I., Aljohani, S.M. and Balkhy, H.H. (2018) Insertion Element Mediated mgrB Disruption and Presence of ISKpn28 in Colistin-Resistant Klebsiella pneumoniae Isolates from Saudi Arabia. Infection and Drug Resistance, 11, 1183-1187. https://doi.org/10.2147/IDR.S161146
|
[19]
|
Abdallah, M. and Balshi, A. (2018) First Literature Review of Carbapenem-Resistant Providencia. New Microbes and New Infections, 25, 16-23.
https://doi.org/10.1016/j.nmni.2018.05.009
|
[20]
|
Skov, R.L. and Monnet, D.L. (2016) Plasmid-Mediated Colistin Resistance (mcr-1 Gene): Three Months Later, the Story Unfolds. Eurosurveillance, 21, 30155.
https://doi.org/10.2807/1560-7917.ES.2016.21.9.30155
|
[21]
|
Liu, Y.-Y., Wang, Y., Walsh, T.R., Yi, L.-X., Zhang, R., Spencer, J., et al. (2016) Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. The Lancet Infectious Diseases, 16, 161-168.
https://doi.org/10.1016/S1473-3099(15)00424-7
|
[22]
|
Baron, S., Hadjadj, L., Rolain, J.M. and Olaitan, A.O. (2016) Molecular Mechanisms of Polymyxin Resistance: Knowns and Unknowns. International Journal of Antimicrobial Agents, 48, 583-591. https://doi.org/10.1016/j.ijantimicag.2016.06.023
|
[23]
|
Rolain, J.M., Kempf, M., Leangapichart, T., et al. (2016) Plasmid-Mediated MCR-1 Gene in Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae in France and Laos. Antimicrobial Agents and Chemotherapy, 60, 6994-6995.
https://doi.org/10.1128/AAC.00960-16
|
[24]
|
Lippa, A.M. and Goulian, M. (2009) Feedback Inhibition in the PhoQ/PhoP Signaling System by a Membrane Peptide. PLOS Genetics, 5, e1000788.
https://doi.org/10.1371/journal.pgen.1000788
|
[25]
|
Wertheim, H., Van Nguyen, K., Hara, G.L., Gelband, H., Laxminarayan, R., Mouton, J., et al. (2013) Global Survey of Polymyxin Use: A Call for International Guidelines. Journal of Global Antimicrobial Resistance, 1, 131-134.
https://doi.org/10.1016/j.jgar.2013.03.012
|
[26]
|
Nation, R.L., Li, J., Cars, O., Couet, W., Dudley, M.N., Kaye, K.S., et al. (2015) Framework for Optimisation of the Clinical Use of Colistin and Polymyxin B: The Prato Polymyxin Consensus. The Lancet Infectious Diseases, 15, 225-234.
https://doi.org/10.1016/S1473-3099(14)70850-3
|
[27]
|
Spapen, H., Jacobs, R., Van Gorp, V., Troubleyn, J. and Honoré, P.M. (2011) Renal and Neurological Side Effects of Colistin in Critically Ill Patients. Annals of Intensive Care, 1, 14.
|
[28]
|
Loho, T. and Dharmayanti, A. (2015) Colistin: An Antibiotic and Its Role in Multiresistant Gram-Negative Infections. Acta Medica Indonesiana, 47, 157-168.
|
[29]
|
Cascio, A., Conti, A., Sinardi, L., Iaria, C., Angileri, F.F. and Stassi, G. (2010) Post-Neurosurgical Multidrug-Resistant Acinetobacter baumannii Meningitis Successfully Treated with Intrathecal Colistin. A New Case and a Systematic Review of the Literature. International Journal of Infectious Diseases, 14, e572-e579.
https://doi.org/10.1016/j.ijid.2009.06.032
|
[30]
|
Markou, N., Markantonis, S.L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., et al. (2008) Colistin Serum Concentrations after Intravenous Administration in Critically Ill Patients with Serious Multidrug-Resistant, Gram-Negative Bacilli Infections: A Prospective, Open-Label, Uncontrolled Study. Clinical Therapeutics, 30, 143-151. https://doi.org/10.1016/j.clinthera.2008.01.015
|
[31]
|
Shibl, A., Al-Agamy, M., Memish, Z., Senok, A., Khader, S.A. and Assiri, A. (2013) The Emergence of OXA-48- and NDM-1-Positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. International Journal of Infectious Diseases, 17, e1130-e1133.
https://doi.org/10.1016/j.ijid.2013.06.016
|
[32]
|
Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. (2009) Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 53, 3430-3436. https://doi.org/10.1128/AAC.01361-08
|
[33]
|
Mohamed, A.F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., et al. (2012) Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrobial Agents and Chemotherapy, 56, 4241-4249.
https://doi.org/10.1128/AAC.06426-11
|
[34]
|
Omrani, A.S., Alfahad, W.A., Shoukri, M.M., Baadani, A.M., Aldalbahi, S., Almitwazi, A.A., et al. (2015) High Dose Intravenous Colistin Methanesulfonate Therapy Is Associated with High Rates of Nephrotoxicity: A Prospective Cohort Study from Saudi Arabia. Annals of Clinical Microbiology and Antimicrobials, 14, 3.
https://doi.org/10.1186/s12941-015-0062-8
|